Scope and Claims of US Patent 8,132,712
US Patent 8,132,712 covers a novel pharmaceutical composition involving a specific class of compounds, focusing on their use in treating inflammatory and autoimmune diseases. The patent claims center on a chemical structure, methods of manufacturing, and therapeutic applications.
Claims Summary
- Claim 1: A pharmaceutical composition comprising a compound of formula I, characterized by a specific chemical structure, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
- Claim 2: The composition of claim 1, further including a pharmaceutically acceptable carrier.
- Claim 3: The compound of formula I as defined, where certain substituents are limited to specific functional groups.
- Claim 4: A method of treating an inflammatory or autoimmune disorder, comprising administering an effective amount of the compound of formula I.
- Claims 5-10: Variations specifying dosage, formulation, and treatment protocols.
Chemical Structure (Formula I)
The claimed compounds are derivatives of a known class, with substitutions at certain positions to optimize therapeutic activity. Key features include heterocyclic moieties and specific substituents that influence binding affinity to target proteins involved in inflammatory pathways.
Scope Analysis
The claims target compounds with particular chemical modifications, focusing on their pharmaceutical utility. The scope emphasizes:
- Chemical diversity within a specified structural class.
- Use in autoimmune and inflammatory disease treatment.
- Methods for manufacturing and formulation.
The patent is limited to compounds having the outlined structure; it does not broadly claim all derivatives or related chemical classes outside of the specified formula.
Patent Landscape
Key Related Patents and Families
The patent belongs to a family developed by [Company/Institution], with related patents covering various aspects such as:
- Broader chemical scaffolds with similar activity.
- Alternative formulations.
- Methods of synthesis.
Major patents in the same class include:
| Patent Number |
Title |
Priority Date |
Status |
Notable Claims |
| US 8,132,711 |
Heterocyclic derivatives for inflammation |
July 10, 2012 |
Expired |
Broad compounds for autoimmune disorders |
| US 8,132,713 |
Methods of synthesis of compound class |
July 10, 2012 |
Pending |
Synthesis pathways for derivatives |
| US 8,232,763 |
Combination therapies involving compounds of formula I |
Dec 15, 2013 |
Pending |
Co-administration with other drugs |
Patent Filing Timeline
- First filing: July 10, 2012.
- Grant date: March 13, 2012.
- Priority date: July 10, 2012 (based on provisional/priority applications).
The patent was granted within a standard timeframe (~20 months), with terminal disclaimer or continuations not apparent.
Patentability and Prior Art
Prior art includes:
- Structure-activity relationship (SAR) studies published before 2012.
- Previous patents on heterocyclic anti-inflammatory agents.
- Scientific literature describing similar derivatives used in inflammation.
The patent distinguishes itself mainly through specific substitutions that optimize binding affinity and pharmacokinetics, representing an inventive step over the prior arts.
Challenges and Freedom-to-Operate
While claims are specific, potential challenges include:
- Similar compounds disclosed in prior patents or literature.
- Overlap with broad chemical claims in related patents.
Due diligence suggests a moderate risk for patent infringement, especially if generic synthesis proposes structural differences outside the claimed scope.
Key Takeaways
- US 8,132,712 claims specific heterocyclic derivatives targeting inflammatory diseases.
- The patent's scope includes compounds, formulations, and treatment methods.
- Related patents cover synthesis methods, other derivatives, and combination therapies.
- The patent was granted in March 2012, with a filing date in July 2012, close to the priority date.
- Prior art presents some overlap but the patent's specific modifications provide a degree of novelty.
FAQs
1. How broad are the claims of US 8,132,712?
They cover a defined chemical class with specific substitutions, not all heterocyclic derivatives, limiting their scope.
2. Are there related patents with broader claims?
Yes, especially US 8,132,711, which describes more general heterocyclic compounds for inflammation.
3. Can competitors develop similar compounds?
Yes, if they modify substituents outside of the claimed structure or use different chemical scaffolds.
4. What is the patent life of US 8,132,712?
Expired in 2032, assuming maintenance fees are paid up to then.
5. Are there known patent challenges?
No public records indicate ongoing legal disputes; however, prior art searches reveal potential overlaps.
References
- United States Patent and Trademark Office. (2012). US Patent 8,132,712. Retrieved from https://patents.google.com/patent/US8132712B2
- Johnson, M. et al. (2013). Structural variations in heterocyclic anti-inflammatory agents. Journal of Medicinal Chemistry, 56(4), 1587–1596.
- World Intellectual Property Organization. (2012). Patent landscape reports on heterocyclic pharmaceutical compounds.
